BioVersys Enrolls First Patient in Phase 2b Trial of BV100 Antibiotic

• BioVersys began enrolling patients in its Phase 2b RIV-CARE trial of BV100 for serious infections caused by carbapenem-resistant Acinetobacter bacteria.
• The approximately 100-patient trial compares BV100-based antibiotic combinations with best available therapy in settings with high drug resistance.
• A previous Phase 2 trial recorded 28-day mortality of 25% with BV100 and polymyxin B, versus 60% with best available therapy.
• Interim RIV-CARE results are expected in the first half of 2027, with final patient enrollment anticipated toward year-end.
• The study complements the ongoing Phase 3 RIV-TARGET trial; initial regulatory submissions for BV100 are anticipated by mid-2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioversys AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2424132_en) on October 29, 2026, and is solely responsible for the information contained therein.